Probiotic supplement targeting bone health to be distributed in the U.S. by Everidis Health Sciences

August 27, 2019

BioGaia (Stockholm, Sweden) has launched a new bone health product called BioGaia Osfortis in the U.S. market, distributed by Everidis Health Sciences (St. Louis, MO). The product is unique because it combines BioGaia’s proprietary Lactobacillus reuteri ATCC PTA 6475 strain with vitamin D. A randomized, placebo-controlled, double-blind study1 published last year found that supplementation with BioGaia’s probiotic strain for 12 months reduced the loss of volumetric bone mineral density by half in elderly women with low bone density, compared to placebo. This research validated results found in animal studies and justified further investigation of the probiotic strain in relation to bone health.

“Osteoporosis is a common, global disease. Consequently, a way of maintaining good bone health constitutes an important focus area for BioGaia. I am very happy that our partner Everidis is launching BioGaia Osfortis in the USA. It is an important market with great potential for this product. Step by step, more markets will launch BioGaia Osfortis,” said Isabelle Ducellier, CEO of BioGaia, in a press release.
 

References: 

1. Nilsson A.G. et al. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo‐controlled, double‐blind, clinical trial." Journal of Internal Medicine, vol. 284, no. 3 (2018): 307-317